Real-world evaluation of CXCL9/10 with PD-L1 and TMB as predictors of pembrolizumab benefit in triple-negative breast cancer (TNBC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Shipra Gandhi, Sachin Kumar Deshmukh, Madison T. Canning, Dario Trapani, Sharon Wu, Jose Pablo Leone, Kevin Kalinsky, Evanthia T. Roussos Torres, Sunil S. Badve, Mayukhmala Jana, Anant Madabhushi, Sahar Almahfouz, Hilmi Al-Shakshir, Maryam B. Lustberg, Kazuaki Takabe, Giuseppe Curigliano, George W. Sledge, Pawel Kalinski
Institutions: Winship Cancer Institute, Caris Life Sciences (United States), Dana-Farber Cancer Institute, University of Southern California, Emory University, Georgia Institute of Technology, Atlanta VA Medical Center, Yale Cancer Center, Roswell Park Comprehensive Cancer Center, University of Milan, European Institute of Oncology, UPMC Hillman Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162569343
Cites:
Cited by:
Related to: